Johannes Wesling Klinikum Minden

Hospital


Location: Minden, Germany (DE) DE

ISNI: 0000000405573596

ROR: https://ror.org/05d89kr76

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort (2022) Freise NF, Gliga S, Fischer J, Lübke N, Lutterbeck M, Schöler M, Bölke E, et al. Journal article EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, et al. Journal article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution Initial and repeat reactions in the European Anaphylaxis Registry a comparative analysis (2022) Hoefer V, Doelle-Bierke S, Rueff F, Hartmann K, Pfoehler C, Treudler R, Wagner N, Worm M Conference contribution Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, et al. Journal article Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. (2022) Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, et al. Journal article
1 2 3 4 5 6 ... 9